questionText: To ask the Secretary of State for Health and Social Care, what discussions his Department has had with NICE and pharmaceutical manufacturers regarding the assessment and potential availability in England of xanomeline-trospium chloride (Cobenfy) for the treatment of schizophrenia.
answerText: Department ministers and officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE), including in relation to the development of guidance on individual products.Xanomeline-trospium chlorid...
heading: Xanomeline/Trospium Chloride